All In Biotech

Drug Trial Radar · NCT07169851

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 204 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

204

Planned (sponsor's estimate)

Start

Nov 28, 2025

Primary completion

Dec 2026

Study completion Feb 2027

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Sep 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to check how well LY35327021 works and how safe it is for controlling nausea and vomiting caused by chemotherapy. Participants who join this study will be in it until all parts are finished, which could take about 2 months.

Conditions

  • Nausea
  • Vomiting
  • Drug-Related Side Effects and Adverse Reactions
  • Neoplasms

Interventions

  • LY3537021Drug

    Administered SC

  • PlaceboDrug

    Administered SC

  • Standard of Care Antiemetic TherapiesDrug

    5-HT3 Receptor Antagonist, NK1 Receptor Antagonist, Dexamethasone administered orally, IV, or transdermally

  • Background ChemotherapyDrug

    Cisplatin or anthraxyline and cyclophosphamide (AC) administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants with a Complete Response (CR) in the Delayed Phase of CINVTime frame: 24 to 120 hours after first chemotherapy infusion

Locations

67 sites in 10 countries. Site status is shown where the registry gives one.

  • Marin Cancer Care

    Greenbrae, California · Recruiting

  • City of Hope Orange County Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Cancer and Blood Specialty Clinic

    Los Alamitos, California · Recruiting

  • BASS Cancer Center

    Walnut Creek, California · Recruiting

  • UCHealth Harmony

    Fort Collins, Colorado · Recruiting

  • BRCR Global - Tamarac

    Tamarac, Florida · Recruiting

  • Summit Cancer Care, PC

    Savannah, Georgia · Recruiting

  • Hope and Healing Cancer Services

    Hinsdale, Illinois · Recruiting

  • Indiana University Melvin and Bren Simon Cancer Center

    Indianapolis, Indiana · Recruiting

  • North Mississippi Hematology and Oncology Associates

    Tupelo, Mississippi · Recruiting

  • Laura and Isaac Perlmutter Cancer Center

    New York, New York · Recruiting

  • New York Cancer and Blood Specialists

    Shirley, New York · Not yet recruiting

  • Oncology Specialists of Charlotte

    Charlotte, North Carolina · Recruiting

  • Southern Oncology Specialists

    Huntersville, North Carolina · Recruiting

  • Asante Rogue Regional Medical Center

    Medford, Oregon · Recruiting

  • World Research Link

    Baytown, Texas · Recruiting

  • John Peter Smith Hospital

    Fort Worth, Texas · Recruiting

  • Kelsey-Seybold Clinic

    Houston, Texas · Recruiting

  • Community Cancer Trials of Utah

    Ogden, Utah · Recruiting

  • Cancer Care Northwest

    Spokane, Washington · Recruiting

  • Ballarat Health Services

    Ballarat Central, Australia · Recruiting

  • Bendigo Health Care Group

    Bendigo, Australia · Recruiting

  • WA Country Health Service Trial Centre

    Perth, Australia · Recruiting

  • Goulburn Valley Health

    Shepparton, Australia · Recruiting

  • Latrobe Regional Health

    Traralgon, Australia · Recruiting

  • The First People's Hospital of Changde City

    Changde, China · Recruiting

  • Zhujiang Hospital

    Guangzhou, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, China · Recruiting

  • Jiangmen Center Hospital

    Jiangmen, China · Recruiting

  • The First Affiliated Hospital of Henan University of Science &Technology

    Luoyang, China · Recruiting

  • Sainte Catherine Institut du Cancer Avignon Provence

    Avignon, France · Active not recruiting

  • Centre Hospitalier d'Annecy

    Epagny Metz-Tessy, France · Recruiting

  • Clinique Victor Hugo Le Mans

    Le Mans, France · Active not recruiting

  • Aou Ospedali Riuniti Umberto I

    Ancona, Italy · Recruiting

  • Azienda Ospedaliero Universitaria

    Modena, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Pisana

    Pisa, Italy · Recruiting

  • AULSS8 Berica-Ospedale S.Bortolo

    Vicenza, Italy · Recruiting

  • Himeji Medical Center

    Himeji, Japan · Recruiting

  • The Cancer Institute Hospital of JFCR

    Kōtoku, Japan · Recruiting

  • Kyoto University Hospital

    Kyoto, Japan · Recruiting

Showing 40 of 67 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.